Hao Tang
Title
Cited by
Cited by
Year
Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
AB El-Khoueiry, B Sangro, T Yau, TS Crocenzi, M Kudo, C Hsu, TY Kim, ...
The Lancet 389 (10088), 2492-2502, 2017
14722017
A community effort to assess and improve drug sensitivity prediction algorithms
JC Costello, LM Heiser, E Georgii, M Gönen, MP Menden, NJ Wang, ...
Nature biotechnology 32 (12), 1202-1212, 2014
4542014
NRF2 regulates serine biosynthesis in non–small cell lung cancer
GM DeNicola, PH Chen, E Mullarky, JA Sudderth, Z Hu, D Wu, H Tang, ...
Nature genetics 47 (12), 1475, 2015
3372015
27-Hydroxycholesterol promotes cell-autonomous, ER-positive breast cancer growth
Q Wu, T Ishikawa, R Sirianni, H Tang, JG McDonald, IS Yuhanna, ...
Cell reports 5 (3), 637-645, 2013
2292013
A 12-gene set predicts survival benefits from adjuvant chemotherapy in non–small cell lung cancer patients
H Tang, G Xiao, C Behrens, J Schiller, J Allen, CW Chow, M Suraokar, ...
Clinical cancer research 19 (6), 1577-1586, 2013
1962013
A community computational challenge to predict the activity of pairs of compounds
M Bansal, J Yang, C Karan, MP Menden, JC Costello, H Tang, G Xiao, ...
Nature biotechnology 32 (12), 1213-1222, 2014
1692014
Human lung epithelial cells progressed to malignancy through specific oncogenic manipulations
M Sato, JE Larsen, W Lee, H Sun, DS Shames, MP Dalvi, RD Ramirez, ...
Molecular cancer research 11 (6), 638-650, 2013
1302013
Use of in Vitro HTS-Derived Concentration–Response Data as Biological Descriptors Improves the Accuracy of QSAR Models of in Vivo Toxicity
A Sedykh, H Zhu, H Tang, L Zhang, A Richard, I Rusyn, A Tropsha
Environmental health perspectives 119 (3), 364-370, 2011
952011
Novel inhibitors of human histone deacetylase (HDAC) identified by QSAR modeling of known inhibitors, virtual screening, and experimental validation
H Tang, XS Wang, XP Huang, BL Roth, KV Butler, AP Kozikowski, M Jung, ...
Journal of chemical information and modeling 49 (2), 461-476, 2009
952009
Prediction of human population responses to toxic compounds by a collaborative competition
F Eduati, LM Mangravite, T Wang, H Tang, JC Bare, R Huang, T Norman, ...
Nature biotechnology 33 (9), 933-940, 2015
882015
An expression signature as an aid to the histologic classification of non–small cell lung cancer
L Girard, J Rodriguez-Canales, C Behrens, DM Thompson, IW Botros, ...
Clinical Cancer Research 22 (19), 4880-4889, 2016
742016
Nivolumab in patients with DNA mismatch repair deficient/microsatellite instability high metastatic colorectal cancer: Update from CheckMate 142.
MJ Overman, S Lonardi, F Leone, RS McDermott, MA Morse, KYM Wong, ...
Journal of Clinical Oncology 35 (4_suppl), 519-519, 2017
642017
Decreased BECN1 mRNA expression in human breast cancer is associated with estrogen receptor-negative subtypes and poor prognosis
H Tang, S Sebti, R Titone, Y Zhou, C Isidoro, TS Ross, H Hibshoosh, ...
EBioMedicine 2 (3), 255-263, 2015
592015
Combinatorial QSAR modeling of specificity and subtype selectivity of ligands binding to serotonin receptors 5HT1E and 5HT1F
XS Wang, H Tang, A Golbraikh, A Tropsha
Journal of chemical information and modeling 48 (5), 997-1013, 2008
342008
Do crystal structures obviate the need for theoretical models of GPCRs for structure‐based virtual screening?
H Tang, XS Wang, JH Hsieh, A Tropsha
Proteins: Structure, Function, and Bioinformatics 80 (6), 1503-1521, 2012
322012
Comprehensive evaluation of published gene expression prognostic signatures for biomarker-based lung cancer clinical studies
H Tang, S Wang, G Xiao, J Schiller, V Papadimitrakopoulou, J Minna, ...
Annals of Oncology 28 (4), 733-740, 2017
312017
DIGRE: Drug‐Induced Genomic Residual Effect Model for Successful Prediction of Multidrug Effects
J Yang, H Tang, Y Li, R Zhong, T Wang, STC Wong, G Xiao, Y Xie
CPT: pharmacometrics & systems pharmacology 4 (2), 91-97, 2015
292015
Adjuvant nivolumab (NIVO) versus ipilimumab (IPI) in resected stage III/IV melanoma: 3-year efficacy and biomarker results from the phase III CheckMate 238 trial
JS Weber, M Del Vecchio, M Mandala, H Gogas, AM Arance, S Dalle, ...
Annals of Oncology 30, v533-v534, 2019
252019
Nivolumab dose escalation and expansion in patients with advanced hepatocellular carcinoma (HCC): The CheckMate 040 study.
I Melero, B Sangro, TC Yau, C Hsu, M Kudo, TS Crocenzi, TY Kim, ...
Journal of Clinical Oncology 35 (4_suppl), 226-226, 2017
252017
Serum IL-6 and CRP as prognostic factors in melanoma patients receiving single agent and combination checkpoint inhibition.
JS Weber, H Tang, L Hippeli, M Qian, M Wind-Rotolo, JMG Larkin, ...
Journal of Clinical Oncology 37 (15_suppl), 100-100, 2019
222019
The system can't perform the operation now. Try again later.
Articles 1–20